Armo Biosciences Inc (NASDAQ:ARMO) Shorts Rose By 18.7%

May 16, 2018 - By Jenna Rose

Armo Biosciences Inc (NASDAQ:ARMO) registered an increase of 18.7% in shares shorted. FINRA issued in May ARMO’s total 1.29 million shares shorted. Previously was reported up change of 18.7% from 1.09 million shares. Former ARMO’s position will need 4 days to recover. It has 357,900 average volume.

ARMO reached $49.85 during the last trading session after $0.02 change.ARMO BioSciences, Inc. has 481,956 shares volume, 25.77% up from normal. ARMO is and has moved 0.00% since May 16, 2017. ARMO underperformed the S&P 500 by 11.55%.

ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States.The firm is worth $1.52 billion. The Company’s lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma.Last it reported negative earnings. The firm is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer.

For more ARMO BioSciences, Inc. (NASDAQ:ARMO) news brought out briefly go to:,,, or The titles are as follows: “Big Peninsula biotech buyout means happy returns for Kleiner Perkins, other VCs” brought out on May 10, 2018, “How this biotech nearly tripled its IPO price with a buyout in less than 4 months” on May 10, 2018, “Week In Review: $3.4 Billion Week For China Life Science Deals” with a publish date: May 13, 2018, “NASDAQ:ARMO Investor Alert: Investigation over Possible Wrongdoing in Acquisition of ARMO BioSciences, Inc” and the last “ARMO BioSciences Announces Poster Presentations of Pegilodecakin (AM0010) at the 2018 American Society of …” with publication date: April 25, 2018.

ARMO BioSciences, Inc. (NASDAQ:ARMO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: